At a glance
ClinicalIndex Comparison RecordPhase 2Unknown· 110 target
Drug / intervention
ZG2001 Tosilate Tabletsdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/II Dose Escalation Study to Evaluating the Tolerability, Safety, Efficacy and Pharmacokinetics of ZG2001 Tosilate Tablets in Participants With KRAS Mutated Advanced Solid Tumours
In Brief
A Phase 2 clinical trial evaluating ZG2001 Tosilate Tablets for Solid Tumor and KRAS Mutation-Related Tumors. Targeting 110 participants across 1 site.
Detailed Summary
This study will evaluate the tolerability, safety, effects, and pharmacokinetics of ZG2001 in Participants with advanced solid tumors that have a KRAS mutation.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumor, KRAS Mutation-Related Tumors
CountriesChina
Collaborators--
Timeline
Phase 2UnknownOverdue
202420252026
Enrollment StartAug 2023
First PostedFeb 2024
Primary CompletionFeb 2026
TodayJul 2026
First PostedFeb 1, 2024
Enrollment StartAug 10, 2023
Primary CompletionFeb 1, 2026
TodayJul 1, 2026
Enrollment to primary: 2.5 yearsPosted 2.4 years ago
Interventions
ZG2001 Tosilate Tabletsdrug
ZG2001 will be administered orally once or twice daily in a continuous regimen